|253.18||-0.6400||-0.25%||Vol 876.78K||1Y Perf 14.60%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||270.45||Analyst Rating||Moderate Buy 2.00|
|Potential %||6.82||Finscreener Ranking||+ 38.56|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★ 45.77|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★ 32.86|
|Price Range Ratio 52W %||70.36||Earnings Rating||Sell|
|Market Cap||72.71B||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||2.42|
|EPS Growth Next 5 Years %||8.30|
|Avg. Weekly Volume||1.25M|
|Avg. Monthly Volume||1.41M|
|Avg. Quarterly Volume||1.30M|
Becton Dickinson and Company (NYSE: BDX) stock closed at 253.18 per share at the end of the most recent trading day (a -0.25% change compared to the prior day closing price) with a volume of 928.28K shares and market capitalization of 72.71B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 72000 people. Becton Dickinson and Company CEO is Thomas E. Polen.
The one-year performance of Becton Dickinson and Company stock is 14.6%, while year-to-date (YTD) performance is 1.18%. BDX stock has a five-year performance of 41.05%. Its 52-week range is between 219.5 and 267.37, which gives BDX stock a 52-week price range ratio of 70.36%
Becton Dickinson and Company currently has a PE ratio of 41.30, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 3.74, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of 3.35%, a ROC of 5.44% and a ROE of 7.54%. The company’s profit margin is 9.83%, its EBITDA margin is 24.30%, and its revenue ttm is $19.90 Billion , which makes it $69.28 revenue per share.
Of the last four earnings reports from Becton Dickinson and Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.42 for the next earnings report. Becton Dickinson and Company’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Becton Dickinson and Company is Moderate Buy (2), with a target price of $270.45, which is +6.82% compared to the current price. The earnings rating for Becton Dickinson and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Becton Dickinson and Company has a dividend yield of 1.28% with a dividend per share of $3.32 and a payout ratio of 57.00%.
Becton Dickinson and Company has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 3.63, CCI20 : -70.17, Chaikin Money Flow : 0.02, MACD : 1.59, Money Flow Index : 48.11, ROC : -3.69, RSI : 45.03, STOCH (14,3) : 6.40, STOCH RSI : 0.00, UO : 36.48, Williams %R : -93.60), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Becton Dickinson and Company in the last 12-months were: Claire M. Fraser-Liggett (Sold 387 shares of value $97 361 ), James Lim (Option Excercise at a value of $1 964 902), James Lim (Sold 6 956 shares of value $1 790 752 ), Rebecca W. Rimel (Sold 1 658 shares of value $424 854 ), Roland Goette (Option Excercise at a value of $267 090), Roland Goette (Sold 930 shares of value $213 993 ), Thomas Spoerel (Sold 266 shares of value $64 452 )
Mon, 09 Aug 2021 12:05 GMT Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX) and Sarepta Therapeutics (SRPT)- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.